SCHEMBL2367657

SCHEMBL2367657

Cc1c(C(=O)O)nnn1Cc1cc(Cl)cc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRN P28799 1/20 0.49
SORT1 Q99523 1/20 0.49
HPGD P15428 1/20 0.48
CYP19A1 P11511 4/20 0.43
KLKB1 P03952 1/20 0.42
MAPT P10636 2/20 0.42
HTT P42858 1/20 0.41
NPC1 O15118 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
CYP1A2 P05177 1/20 0.40
GALR3 O60755 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
NR2F2 P24468 1/20 0.40
HIF1A Q16665 1/20 0.40
TSHR P16473 1/20 0.39
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2367593 0.86 HPGD (0.53) HPGDCYP19A1KLKB1MAPTNPC1
SCHEMBL4638825 0.85 HPGD (0.50) GRNSORT1HPGDCYP19A1MAPT
SCHEMBL2368220 0.85 CYP1A2 (0.52) GRNSORT1HPGDCYP19A1KLKB1
SCHEMBL25333493 0.83 CYP19A1 (0.56) HPGDCYP19A1MAPTSMN1; SMN2
SCHEMBL795210 0.83 HPGD (0.68) HPGDCYP19A1KLKB1MAPTHTT
SCHEMBL2367846 0.82 HPGD (0.54) HPGDCYP19A1KLKB1MAPTHTT
SCHEMBL1923196 0.82 HPGD (0.48) HPGDKLKB1HTTSMN1; SMN2CYP2C9
SCHEMBL2367545 0.80 HPGD (0.49) HPGDCYP19A1KLKB1HTTSMN1; SMN2
SCHEMBL2367880 0.79 CYP19A1 (0.53) HPGDCYP19A1KLKB1MAPTHTT
SCHEMBL2368342 0.79 POLB (0.53) HPGDCYP19A1KLKB1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129031-A1 1,2,3-TRIAZOLE CARBONYL SULFONYLAMIDE COMPOUNDS AND USE THEREOF PI INDUSTRIES LTD (IN) 2025-04-24 US disclosed
EP-4469442-A1 1,2,3-TRIAZOLE CARBONYL SULFONYLAMIDE COMPOUNDS AND USE THEREOF PI Industries Ltd. (IN) 2024-12-04 EP disclosed
CN-118696033-A 1,2, 3-Triazole carbonyl sulfonamide compound and application thereof PI工业有限公司 2024-09-24 CN disclosed
WO-2023144711-A1 1,2,3-TRIAZOLE CARBONYL SULFONYLAMIDE COMPOUNDS AND USE THEREOF PI INDUSTRIES LTD. (IN) 2023-08-03 WO disclosed
US-9051281-B2 Compounds GLAXOSMITHKLINE LLC (US) 2015-06-09 US disclosed
US-9051281-B2 Compounds GLAXOSMITHKLINE LLC (US) 2015-06-09 US disclosed
US-9051281-B2 Compounds GLAXOSMITHKLINE LLC (US) 2015-06-09 US disclosed
EP-2368887-B1 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-02-26 EP disclosed
US-20130281499-A1 COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2013-10-24 US disclosed
US-20130281499-A1 COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2013-10-24 US disclosed
US-20130281499-A1 COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2013-10-24 US disclosed
US-8486977-B2 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors GLAXOSMITHKLINE LLC (US) 2013-07-16 US disclosed
US-8486977-B2 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors GLAXOSMITHKLINE LLC (US) 2013-07-16 US disclosed
US-8486977-B2 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors GLAXOSMITHKLINE LLC (US) 2013-07-16 US disclosed
EP-2368887-A1 1, 2, 3-triazole derivatives for use as stearoyl-COA desaturase inhibitors Glaxosmithkline LLC (US) 2011-09-28 EP disclosed
US-20100297054-A1 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-11-25 US disclosed
US-20100297054-A1 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-11-25 US disclosed
US-20100297054-A1 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-11-25 US disclosed
WO-2009060053-A1 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129031-A1 1,2,3-TRIAZOLE CARBONYL SULFONYLAMIDE COMPOUNDS AND USE THEREOF GLP1R, CBR3, CBR1 GRN 4653/4885SORT1 4058/4885HPGD 4556/4885
US-20100297054-A1 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS SCD, SCD5, FASN GRN 4760/4885SORT1 2433/4885HPGD 592/4885
US-20130281499-A1 COMPOUNDS CYP11B2, SCD, CYP11B1 GRN 1492/4885SORT1 2053/4885HPGD 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.